When is the realignment for chronic care?

Quote




































Maybe not all lights out but skeleton sales force. I am sad to see this. I’ve had a great career at Merck. Some will choose to complain but no one has made you stay. It’s been a great run.
 


















anonymous said:
Do they usually let go people with less or more years with the company?
Click to expand...

I have been through several of these and I have seen both tenure & newly hired get placed. This one will be different because the DCO’s don’t have any input. Sr. Leadership and HR will be deciding everyone’s fate. It’s anyone’s guess at this point. I feel that I don’t even have a shot because I live in a big Metropolitan area. Best of luck to you.
 






anonymous said:
Maybe not all lights out but skeleton sales force. I am sad to see this. I’ve had a great career at Merck. Some will choose to complain but no one has made you stay. It’s been a great run.
Click to expand...

I couldn’t agree with you more, CC or Primary Care as it used to be called has a great history of medicines. Mevacor, Zocor, Vytorin, Singular, Fosamax, Januvia to name a few. In 2009 Merck merged with Schering-Plough. We became the respiratory experts, unmatched by any other pharmaceutical company in the industry. When you say, you are sad to see this, I’m sad Merck has transitioned away from primary care and set a path on Cancer Medicines. Who can blame management, Keytruda will make $25 Billion dollars this year. Good luck to everyone.
 






anonymous said:
it is confirmed, the FDA rejects gefapixant. Lights out for chronic care.
Click to expand...

Can somebody tell me how the hell Joerg Koglin got his job? This is by far the most idiotic statement I have ever heard about a rejection of a medicine. Just because there is no FDA approved medicine for something means you must approve this snake oil??

“Acknowledging the absence of any approved treatments for refractory or unexplained chronic cough, we are disappointed in the FDA’s response to our application for gefapixant,” Joerg Koglin, senior vice president of global clinical development at Merck Research Laboratories, said.

If I’m wrong please someone tell me.
 












anonymous said:
I couldn’t agree with you more, CC or Primary Care as it used to be called has a great history of medicines. Mevacor, Zocor, Vytorin, Singular, Fosamax, Januvia to name a few. In 2009 Merck merged with Schering-Plough. We became the respiratory experts, unmatched by any other pharmaceutical company in the industry. When you say, you are sad to see this, I’m sad Merck has transitioned away from primary care and set a path on Cancer Medicines. Who can blame management, Keytruda will make $25 Billion dollars this year. Good luck to everyone.
Click to expand...

Respiratory experts? ROTFLMAO
 


















anonymous said:
Do they let go newer or more experienced reps? Lower or higher salary?
Click to expand...

Understand that however they make decisions on separation that one of the first concerns is risk to the organization. Great efforts are made to remove subjectivity and use objective measures instead. In recent displacements things like competencies (a subjective assesment converted to objective through numeric scoring by Mgt.), maintaining existing customer relationships, distance to center of workload to name a few. THEN final decisions are not made by management (where subjective bias could be asserted) but rather HR or HR in concert with an outside consultant. Generally they get it pretty right but there are always some head scratchers. After going through this several times what I can share confidently is those displaced, be it unsettling at best, will end up finding other work and doing just fine. Best to all those caugfht up in this, things will get better.
 


















Um, hello. We have nothing to sell. Belsomra gone, cough med dead. Verquvo? Most territories aren’t even getting 1 script a week. Figure it out, cuts are going to be huge.
 






Top Bottom
Back
Quote